Open AccessZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS
Author(s) -
Svetlana Vorotnikova,
Е А Пигарова
Publication year - 2016
Publication title -
osteoporoz i osteopatii
Language(s) - English
Resource type - Journals
eISSN - 2311-0716
pISSN - 2072-2680
DOI - 10.14341/osteo2016323-27
Subject(s) - zoledronic acid , osteogenesis imperfecta , medicine , osteoporosis , bone density conservation agents , primary hyperparathyroidism , clinical trial , bone disease , bisphosphonate , oncology , dentistry , bone density , pathology
The data from a number of clinical trials investigating a once-yearly infusion of5 mg zoledronic acidshow a marked efficacy of this intervention in the treatment of primary and secondary osteoporosis with a combination of fracture risk reduction and prevention of bone loss at key skeletal sites. Recent research studies demonstrate beneficial features of original and generic zoledronic acid for treatment of patients with osteogenesis imperfecta, primary hyperparathyroidism, Paget’s disease of bone,vertebroplasty and dental implantation.